Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk
BEVESPI AEROSPHERE is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD1
For illustration purposes only. Not to scale.
Induces bronchodilation through inhibition of the M3 receptor at the smooth muscle1
Rapidly and effectively relaxes the central and peripheral airways1
Recommended and maximum BEVESPI dose is1:
If a dose is missed, it should be taken as soon as possible and the next dose should be taken at the usual time. A double dose should not be taken to make up for a forgotten dose.1
An overdose of BEVESPI AEROSPHERE may lead to exaggerated anticholinergic and/or β2-adrenergic signs and symptoms, the most frequent of which include blurred vision, dry mouth, nausea, muscle spasm, tremor, headache, palpitations and systolic hypertension.1
If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.
At 5 minutes following administration of the first dose on day 1, there was significant improvement in FEV1 from baseline vs placebo (in PINNACLE-1 and PINNACLE-2 studies respective differences were 187 and 186 mL, all p<0.0001)1,4
Aerosphere technology enables effective, consistent dose delivery to the whole lung with lung deposition of 38.4% with BEVESPI AEROSPHERE.5¶
BEVESPI AEROSPHERE demonstrated statistically significant improvements in trough FEV1 at 24 weeks vs both monocomponents4,6,7
Improvement of Health-related quality-of-life (SGRQ scores) with Bevespi was statistically but not clinically significant at Week 24 vs placebo in PINNACLE-1, PINNACLE-2, and PINNACLE-4 trials.1,4‡
*PINNACLE 1: 59 mL vs glycopyrrolate and 64 mL vs formoterol (both p<0.0001); PINNACLE 2: 54 mL vs glycopyrrolate (p<0.0003) and 56 mL vs formoterol (p<0.0002); PINNACLE 4: 59 mL vs glycopyrrolate and 72 mL vs formoterol (both p<0.0001).
‡Health-related quality of life was measured using the SGRQ. An improvement of 4 points in the SGRQ total score is the minimal clinically important difference.4
¶Based on a phase 1 trial of radiolabelled BEVESPI vs radiolabelled placebo pMDI (n=10). The dose detected in the oropharyngeal and stomach regions was 61% and 67% for BEVESPI and placebo, respectively.5
The most common adverse reactions with BEVESPI AEROSPHERE (n=1588) were headache (1.9%), nausea (1.4%), muscle spasms (1.4%), and dizziness (1.3%). Other common adverse reactions included anxiety, dry mouth, chest pain, and urinary tract infection. For full list of adverse reactions please refer to BEVESPI SmPC.1
Access BEVESPI patient resources here
FEV1, forced expiratory volume in first second; ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist; LAMA, long-acting muscarinic antagonist; SGRQ, St George’s Respiratory Questionnaire, pMDI, pressurised metered dose inhaler; COPD, chronic obstructive pulmonary disease, n, number of patients
BEVESPI, TRIXEO and AEROSPHERE are registered trademarks of the AstraZeneca group of companies.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
